DiaMedica Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 USD | -3.47% | -4.08% | +7.75% |
05-09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
04-17 | DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.75% | 116M | |
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke